- Home
- ONCY
as 07-26-2024 4:00pm EST
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatment. The other projects in the company's pipeline include, Bracelet-1 for treatment of Breast Cancer, Goblet cohort-1, Goblet cohort-5 for treatment of Gastro-Intestinal Cancer among others.
| Founded: | 1998 | Country: | Canada |
| Employees: | N/A | City: | N/A |
| Market Cap: | 78.4M | IPO Year: | 1999 |
| Target Price: | $4.00 | AVG Volume (30 days): | 142.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.40 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.88 - $2.81 | Next Earning Date: | 08-12-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 731.35% |
Latest Oncolytics Biotech Inc. News
ONCY Breaking Stock News: Dive into ONCY Ticker-Specific Updates for Smart Investing
Simply Wall St.
2 days ago
Here's Why We're Watching Oncolytics Biotech's (TSE:ONC) Cash Burn Situation
CNW Group
3 days ago
Oncolytics Biotech® to Host Conference Call to Discuss Second Quarter Financial Results and Recent Operational Highlights
MT Newswires
a month ago
Oncolytics Biotech UP 1.9% In US Premarket Announces "Productive" FDA Type C Meeting on Metastatic Breast Cancer Program
CNW Group
a month ago
Oncolytics Biotech® Announces Productive FDA Type C Meeting on its Metastatic Breast Cancer Program
MT Newswires
a month ago
Oncolytics Biotech CEO Matt Coffey to Take Medical Leave of Absence
MT Newswires
a month ago
Oncolytics Biotech President and CEO Coffey to Take Medical Leave of Absence
PR Newswire
a month ago
Oncolytics Biotech® Announces President and Chief Executive Officer Dr. Matt Coffey to Take Medical Leave of Absence
Clinical Trials Arena
a month ago
Oncolytics doses first subject in pancreatic cancer trial
Compare ONCY vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ONCY Oncolytics Biotech Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.